Mereo Biopharma
Mereo Biopharma Group plc, commonly referred to as Mereo Biopharma, is a pioneering biopharmaceutical company headquartered in Great Britain. Founded in 2015, the company focuses on developing innovative therapies for patients with rare diseases and unmet medical needs, particularly in the fields of oncology and metabolic disorders. Mereo Biopharma's core products, including its unique therapeutic candidates, are designed to address significant gaps in current treatment options, showcasing the company's commitment to advancing healthcare. With a strong emphasis on clinical development, Mereo has achieved notable milestones, including successful clinical trials that position it as a key player in the biopharma industry. As it continues to expand its operational reach, Mereo Biopharma is dedicated to delivering transformative solutions that enhance patient outcomes and solidify its market presence.
DitchCarbon Score
How does Mereo Biopharma's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Mereo Biopharma's score of 14 is lower than 91% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Mereo Biopharma's reported carbon emissions
In 2022, Mereo Biopharma, headquartered in Great Britain, reported an employee-related carbon footprint of approximately 460 kg CO2e per employee. This figure reflects the company's total emissions but does not specify Scope 1, 2, or 3 emissions, as no detailed emissions data has been disclosed for these categories. In 2021, the company reported a slightly higher employee-related carbon footprint of about 490 kg CO2e per employee. Currently, Mereo Biopharma has not established any specific reduction targets or initiatives, nor does it participate in recognised climate pledges such as the Science Based Targets initiative (SBTi). The absence of disclosed emissions data and reduction commitments indicates that the company may still be in the early stages of developing a comprehensive climate strategy. As Mereo Biopharma continues to grow, it may consider implementing more robust climate commitments to align with industry standards and expectations for sustainability.
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Mereo Biopharma is not participating in any of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
